Wall St. Cheat SheetWall St. Cheat Sheet – 2 hours 49 minutes ago
S&P 500 component Thermo Fisher Scientific, Inc. will unveil its latest earnings on Wednesday, February 1, 2012. Thermo Fisher Scientific develops, manufactures and sells products to assist the pharmaceutical, biotechnology, academic, government and other research and industrial markets.
Thermo Fisher Scientific, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for net income of $1.15 per share, a rise of 15% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.16. Between one and three months ago, the average estimate was unchanged. It has since dropped over the last month. For the year, analysts are projecting profit of $4.13 per share, a rise of 15.7% from last year.
Past Earnings Performance: Last quarter, the company saw net income of $1.07 per share versus a mean estimate of profit of $1.07 per share. This comes after two consecutive quarters of exceeding expectations.
Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?
Wall St. Revenue Expectations: On average, analysts predict $3.08 billion in revenue this quarter, a rise of 10.8% from the year ago quarter. Analysts are forecasting total revenue of $11.66 billion for the year, a rise of 8.1% from last year’s revenue of $10.79 billion.
Analyst Ratings: Analysts are bullish on this stock with 14 analysts rating it as a buy, none rating it as a sell and two rating it as a hold.
A Look Back: In the third quarter, profit fell 1.2% to $265.4 million (69 cents a share) from $268.5 million (66 cents a share) the year earlier, meeting analyst expectations. Revenue rose 10.8% to $2.97 billion from $2.68 billion.
Key Stats:
The decrease in profit in the third quarter broke a streak of three consecutive quarters of year-over-year profit increases. Net income rose more than twofold in the second quarter, 8.6% in the first quarter and 8.9% in the fourth quarter of the last fiscal year.
Revenue has gone up for three straight quarters. It rose 9.4% in the second quarter from the year earlier and 1.7% in the first quarter.
Competitors to Watch: PerkinElmer, Inc. , Becton, Dickinson and Co. , Bruker Corporation , Beckman Coulter, Inc. , Harvard Bioscience, Inc. , Bio-Rad Laboratories, Inc. , CareFusion Corporation , Waters Corporation , Teleflex Incorporated , and Quidel Corporation .
Stock Price Performance: During December 27, 2011 to January 26, 2012, the stock price had risen $6.81 (15%) from $45.50 to $52.31. The stock price saw one of its best stretches over the last year between May 5, 2011 and May 16, 2011 when shares rose for eight-straight days, rising 4.3% (+$2.59) over that span. It saw one of its worst periods between March 11, 2011 and March 18, 2011 when shares fell for six-straight days, falling 4.8% (-$2.67) over that span.
Recent HBIO News
- Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 10:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:04:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 12:00:19 PM
- Harvard Bioscience Announces Fourth Quarter 2023 Financial Results • GlobeNewswire Inc. • 03/07/2024 12:00:00 PM
- Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting • GlobeNewswire Inc. • 03/06/2024 01:30:00 PM
- Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET • GlobeNewswire Inc. • 02/27/2024 10:10:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:05:25 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:00:05 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:46:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 10:01:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:18:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:17:24 PM
- Harvard Bioscience to Present at Benchmark Company’s Discovery One-On-One Investor Conference on December 7, 2023 • GlobeNewswire Inc. • 11/20/2023 09:40:00 PM
- Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023 • GlobeNewswire Inc. • 11/09/2023 09:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:45:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:00:39 PM
- Harvard Bioscience Announces Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 12:00:00 PM
- Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023 • GlobeNewswire Inc. • 11/06/2023 09:30:00 PM
- Harvard Bioscience Schedules Third Quarter 2023 Earnings Conference Call for November 7, 2023 at 8:00 AM ET • GlobeNewswire Inc. • 10/30/2023 01:00:00 PM
- Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research • GlobeNewswire Inc. • 09/18/2023 12:57:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2023 08:06:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 09:06:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 01:05:43 PM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM